- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pfizer and Morgan State University Launch Vaccine Fellowship
Pfizer and Morgan State University’s program, a Doctor of Public Health (DrPH) Fellowship in Vaccines Medical Development, will officially begin on August 30th. The collaboration with Morgan State University is part of Pfizer’s continued partnership with Historically Black Colleges and Universities (HBCUs).
The two-year program aims to expand the number of minority scholar practitioners in the fields of medical development, as well as vaccine-related real-world data and analysis. The program will provide fellows the opportunity to:
- Contribute and lead in medical, clinical, and scientific affairs related to vaccines.
- Partner with key thought leaders, professional societies, and patient advocacy groups to identify areas of unmet medical need.
- Gain invaluable training and networking opportunities to pursue a successful career in the biopharmaceutical industry.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
